- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Roquefort Theraptcs. - Research Note Published | - | RNS | ||
| 12.12.25 | Roquefort Theraptcs. - Clinical Trial & License Agreement Update | 2 | RNS | ||
| 11.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 11.12.2025 | 502 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.12.2025
Aktien
1 AU0000410128 Ariana Resources PLC
2... ► Artikel lesen | |
| ROQUEFORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | Roquefort Theraptcs. - Conversion of CLNs | - | RNS | ||
| 01.12.25 | Roquefort Therapeutics: Aktie handelt ab heute ex-Anspruch auf unkotierte Aktien | 2 | Investing.com Deutsch | ||
| 01.12.25 | Roquefort Therapeutics shares marked ex-entitlement for unlisted shares | 1 | Investing.com | ||
| 01.12.25 | Roquefort Theraptcs. - Ex-Entitlement Date - Unlisted RNV Shares | - | RNS | ||
| 01.12.25 | Roquefort Theraptcs. - Determination of Record Date and Entitlement | - | RNS | ||
| 24.11.25 | Director dealings: Roquefort Therapeutics director raises stake | 1 | Sharecast | ||
| 24.11.25 | Roquefort Theraptcs. - Director/PDMR Shareholding | - | RNS | ||
| 18.11.25 | Roquefort Theraptcs. - Executed License Agreement & Transaction Update | - | RNS | ||
| 03.11.25 | Roquefort Theraptcs. - MK Cell Out-License & Lyramid SPA Update | - | RNS | ||
| 16.10.25 | Roquefort Therapeutics beschafft 300.000 £ für Akquisition von Krebsmedikament | 1 | Investing.com Deutsch | ||
| 16.10.25 | Roquefort Therapeutics raises £300,000 to fund cancer drug acquisition | 2 | Investing.com | ||
| 16.10.25 | Roquefort Theraptcs. - Fundraise & Transaction Update | - | RNS | ||
| 30.09.25 | EARNINGS: Billington profit dives; Emmerson and Roquefort Therapeutics narrow loss | 2 | Alliance News | ||
| 30.09.25 | Roquefort Theraptcs. - Interim Results to 30 June 2025 | - | RNS | ||
| 24.09.25 | Roquefort Theraptcs. - Investor Presentation via Engage Investor | - | RNS | ||
| 08.09.25 | Roquefort Therapeutics shares surge on Coiled USA reverse takeover proposal | 1 | Alliance News | ||
| 08.09.25 | Roquefort Theraptcs. - Proposed Acquisition of Clinical Stage Company | - | RNS |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,360 | +1,40 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen ROQUEFORT THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,009 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ROQUEFORT THERAPEUTICS PLC finden Sie auf Wallstreet Online.